MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ
4.405
-0.190
-4.13%
Opening 15:32 03/16 EDT
OPEN
4.690
PREV CLOSE
4.595
HIGH
4.775
LOW
4.350
VOLUME
1.78M
TURNOVER
--
52 WEEK HIGH
6.42
52 WEEK LOW
1.610
MARKET CAP
456.32M
P/E (TTM)
-2.2853
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LRMR last week (0309-0313)?
Weekly Report · 14h ago
Larimar Advances Nomlabofusp Toward 2026 BLA Submission
TipRanks · 03/09 20:33
Weekly Report: what happened at LRMR last week (0302-0306)?
Weekly Report · 03/09 09:39
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference and Citizens Life Sciences Conference
Reuters · 03/04 21:08
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
Barchart · 03/04 15:05
Larimar Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones · 03/03 15:14
Wedbush Maintains Outperform on Larimar Therapeutics, Raises Price Target to $12
Benzinga · 03/03 15:05
Larimar Therapeutics price target raised to $12 from $11 at Wedbush
TipRanks · 03/03 13:50
More
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.

Webull offers Larimar Therapeutics Inc stock information, including NASDAQ: LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.